SUBSCRIBE
SUBSCRIBE

Krystle Vermes

Biotech Beach
Researchers Eye Trifluoperazine as a Potential Treatment for Glioblastoma
UCLA Jonsson Comprehensive Cancer Center researchers and their colleagues announced on May 1 that they have discovered a drug that may help improve the overall survival rate in glioblastoma patients.
May 4, 2020
 · 
3 min read
 · 
Krystle Vermes
Business
Notable and MDS Foundation Partner on MDS Trials and New Drug Therapies
Notable will offer a grant to support the MDS Foundation’s education and advocacy efforts, and both companies will work closely to engage physicians, biopharmaceutical companies, health authorities and clinical trial organizations to collaborate on clinical trial designs.
May 1, 2020
 · 
3 min read
 · 
Krystle Vermes
Genetown
Researchers Develop Macrophage ‘Backpacks’ to Combat Tumors in Mice
These “backpacks” keep key immune cells in a tumor-killing state for up to five days after they approach a tumor.
April 30, 2020
 · 
3 min read
 · 
Krystle Vermes
Business
Almac Discovery and Merck Partner to Develop Inhibitors Against DUB Targets
Together, the companies will focus on the generation of novel small molecule inhibitors against specified deubiquitinase (DUB) targets, specifically for the treatment of neurodegenerative and other diseases.
April 29, 2020
 · 
3 min read
 · 
Krystle Vermes
FDA approved Ascendis Pharma’s Skytrofa.
FDA
Neurocrine Biosciences Receives FDA Approval for Ongentys, Opts to Delay Launch
Neurocrine Biosciences announced on Monday that it has received approval from the U.S. Food and Drug Administration for its once-daily oral drug, Ongentys, as an add-on treatment to levodopa/carbidopa for the treatment of Parkinson’s disease.
April 28, 2020
 · 
3 min read
 · 
Krystle Vermes
Close up of Businessman pointing and signing agreement contract for buying house. Bank manager and real estate concept.
Business
Takeda and ProThera Enter Agreement to Develop Novel IAIP Therapy
“Our goal is to successfully treat patients with severe inflammatory conditions and this is now possible through our alliance with Takeda,” said Denice Spero, president and chief business officer of ProThera.
April 24, 2020
 · 
3 min read
 · 
Krystle Vermes
Genetown
Study Shows Coronavirus Could Be Attacking Certain Cells in the Body
“Our goal is to get information out to the community and to share data as soon as is humanly possible, so that we can help accelerate ongoing efforts in the scientific and medical communities,” said Alex K. Shalek, the Pfizer-Laubach Career Development Associate Professor of Chemistry.
April 23, 2020
 · 
2 min read
 · 
Krystle Vermes
Biotech Bay
Gilead, Kite and oNKO-innate Announce Pact to Focus on NK Cells for Immunotherapy
The goal is to support the discovery and development of next-generation drug and engineered cell therapies, specifically with a focus on natural killer (NK) cells.
April 22, 2020
 · 
3 min read
 · 
Krystle Vermes
Doxorubicin
BioMidwest
Low Doses of Doxorubicin May Be Key to Fighting Drug-Resistant Cancer
According to the research, published in Nature Cell Biology, targeted doses of doxorubicin could potentially inhibit the interaction between two molecular pathways that work together to encourage tumor growth.
April 21, 2020
 · 
3 min read
 · 
Krystle Vermes
Drug Development
Idorsia Moves Forward with Experimental Insomnia Drug After Positive Phase III Trial
“The excellent results seen in this Phase III study of 3-month duration suggest that daridorexant can fulfill this significant need for patients with insomnia,” said Dr. Thomas Roth, PhD, Director of the Sleep Disorder and Research Center at Henry Ford Hospital.
April 20, 2020
 · 
3 min read
 · 
Krystle Vermes
Load More